China Universal Asset Management Co., Ltd. Pliant Therapeutics, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$773 Million
Q1 2024

A detailed history of China Universal Asset Management Co., Ltd. transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 11,581 shares of PLRX stock, worth $121,832. This represents 0.02% of its overall portfolio holdings.

Number of Shares

11,581

Previous 11,581 -0.0%

Holding current value

$121,832

Previous $173,000 0.58%

% of portfolio

0.02%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$14.14 - $19.59 $65,779 - $91,132	4,652 Added 67.14%	11,581 $173,000
Q4 2023 May 21, 2024	SELL	$12.85 - $19.15 $59,778 - $89,085	-4,652 Reduced 40.17%	6,929 $125,000
Q4 2023 Jan 23, 2024	BUY	$12.85 - $19.15 $69,390 - $103,409	5,400 Added 353.17%	6,929 $125,000
Q3 2023 May 21, 2024	BUY	$14.58 - $20.15 $10,993 - $15,193	754 Added 97.29%	1,529 $26,000
Q3 2023 Oct 30, 2023	BUY	$14.58 - $20.15 $10,993 - $15,193	754 Added 97.29%	1,529 $27,000

Q2 2023 May 21, 2024	BUY	$18.12 - $30.56 $36 - $61	2 Added 0.26%	775 $14,000
Q2 2023 Jul 27, 2023	BUY	$18.12 - $30.56 $36 - $61	2 Added 0.26%	775 $14,000
Q1 2023 May 21, 2024	BUY	$18.73 - $36.26 $5,206 - $10,080	278 Added 56.16%	773 $20,000
Q1 2023 Apr 27, 2023	BUY	$18.73 - $36.26 $5,206 - $10,080	278 Added 56.16%	773 $21,000
Q4 2022 May 21, 2024	SELL	$17.0 - $25.43 $188,462 - $281,916	-11,086 Reduced 95.73%	495 $9,000
Q4 2022 Jan 31, 2023	BUY	$17.0 - $25.43 $663 - $991	39 Added 8.55%	495 $10,000
Q3 2022 Oct 21, 2022	BUY	$7.67 - $24.23 $3,497 - $11,048	456 New	456 $10,000

Others Institutions Holding PLRX

# of Institutions

148

Shares Held

63.8M

Call Options Held

417K

Put Options Held

123K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $512M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account

China Universal Asset Management Co., Ltd. Pliant Therapeutics, Inc. Transaction History